The stock of MacroGenics Inc (NASDAQ:MGNX) is a huge mover today! The stock decreased 5.64% or $1.55 during the last trading session, hitting $25.93. About 197,278 shares traded hands. MacroGenics Inc (NASDAQ:MGNX) has risen 30.36% since April 27, 2016 and is uptrending. It has outperformed by 25.13% the S&P500.
The move comes after 8 months negative chart setup for the $908.91 million company. It was reported on Nov, 30 by Barchart.com. We have $24.89 PT which if reached, will make NASDAQ:MGNX worth $36.36M less.
Analysts await MacroGenics Inc (NASDAQ:MGNX) to report earnings on March, 6. They expect $-0.81 EPS, up 8.99% or $0.08 from last year’s $-0.89 per share. After $-0.97 actual EPS reported by MacroGenics Inc for the previous quarter, Wall Street now forecasts -16.49% EPS growth.
MacroGenics Inc (NASDAQ:MGNX) Ratings Coverage
Out of 4 analysts covering MacroGenics (NASDAQ:MGNX), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. MacroGenics has been the topic of 8 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Citigroup downgraded the stock to “Neutral” rating in Thursday, August 4 report. The company was initiated on Thursday, February 25 by Morgan Stanley. The stock of MacroGenics Inc (NASDAQ:MGNX) has “Buy” rating given on Monday, October 19 by Citigroup. The rating was initiated by Citigroup on Thursday, September 17 with “Neutral”. The stock of MacroGenics Inc (NASDAQ:MGNX) earned “Buy” rating by Janney Capital on Thursday, February 18. Zacks downgraded the shares of MGNX in a report on Monday, August 10 to “Buy” rating. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, August 6.
According to Zacks Investment Research, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland.”
Insitutional Activity: The institutional sentiment increased to 1.43 in Q2 2016. Its up 0.22, from 1.21 in 2016Q1. The ratio increased, as 14 funds sold all MacroGenics Inc shares owned while 34 reduced positions. 13 funds bought stakes while 45 increased positions. They now own 27.76 million shares or 2.47% less from 28.46 million shares in 2016Q1.
Blackrock Incorporated accumulated 2,699 shares or 0% of the stock. Blackrock Fund has invested 0.01% of its portfolio in MacroGenics Inc (NASDAQ:MGNX). Great West Life Assurance Can owns 2,500 shares or 0% of their US portfolio. The New York-based Art Advsr Ltd Liability Company has invested 0.02% in MacroGenics Inc (NASDAQ:MGNX). Blackrock Advisors Ltd Llc last reported 19,665 shares in the company. Oxford Asset Management, a United Kingdom-based fund reported 96,417 shares. Blackrock Institutional Tru Na has 720,407 shares for 0% of their US portfolio. Paradigm Asset Management Co Ltd Liability holds 0% of its portfolio in MacroGenics Inc (NASDAQ:MGNX) for 600 shares. Balyasny Asset Mgmt has invested 0.03% of its portfolio in MacroGenics Inc (NASDAQ:MGNX). Millennium Ltd Liability Corporation accumulated 0% or 70,000 shares. Spc Financial Inc, a Maryland-based fund reported 37,750 shares. Moreover, Tudor Et Al has 0.01% invested in MacroGenics Inc (NASDAQ:MGNX) for 12,858 shares. State Street has 0% invested in the company for 715,507 shares. Jpmorgan Chase & has 0% invested in the company for 218,891 shares. Tanaka Capital has 26,170 shares for 1.81% of their US portfolio.
Insider Transactions: Since July 1, 2016, the stock had 0 buys, and 5 insider sales for $1.47 million net activity. The insider Wigginton Jon Marc sold 5,000 shares worth $136,100. 6,231 MacroGenics Inc (NASDAQ:MGNX) shares with value of $182,444 were sold by Cilinski Lynn.
More recent MacroGenics Inc (NASDAQ:MGNX) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on November 04, 2013. Also Globenewswire.com published the news titled: “MacroGenics Enters Collaboration and License Agreement with Janssen to Develop …” on May 18, 2016. Bizjournals.com‘s news article titled: “MacroGenics begins expansion following $141M round” with publication date: August 14, 2015 was also an interesting one.
MGNX Company Profile
MacroGenics, Inc., incorporated on August 14, 2000, is a clinical-stage biopharmaceutical firm focused on discovering and developing monoclonal antibody therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Firm operates through developing monoclonal antibody therapeutics for cancer, autoimmune and infectious diseases segment. The Firm develops therapeutic product candidates using its antibody technology platforms and in partnership with other biopharmaceutical companies. The Firm has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created primarily using its technology platforms.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.